Icatibant Teva (Icatibant Acetate)

Icatibant is a selective antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑mediated vasodilation and increased vascular permeability, which are the primary drivers of swelling in hereditary angioedema.

The dose of Icatibant Teva is determined by the prescribing clinician based on the patient’s condition and regulatory guidelines. It is administered as a subcutaneous injection, and the exact regimen should be confirmed with the treating physician.

Safety data for icatibant in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling), and any necessary import documentation.

The primary alternative for HAE attacks is plasma‑derived C1‑esterase inhibitor replacement therapy. Icatibant offers a subcutaneous, self‑administered option that directly blocks bradykinin, whereas C1‑esterase inhibitors replace the deficient protein. Choice depends on patient preference, attack severity, and clinical response.

Icatibant Teva must be stored refrigerated at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary temperature excursions occur, consult the supplier before use.

Icatibant is given as a single subcutaneous injection into the abdomen, thigh, or upper arm. The injection site should be rotated for repeated doses, and patients should be instructed on proper aseptic technique and disposal of sharps according to local regulations.

Serious adverse events include hypersensitivity reactions such as anaphylaxis, severe hypotension, and worsening angioedema that may involve the airway. Immediate medical attention is required if any of these symptoms develop after administration.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant acetate or any excipients in the formulation. It should also be avoided in patients receiving other bradykinin B2 receptor antagonists or ACE inhibitors when alternative therapies are available.